We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+19.05%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.5B
AUM Growth
–
Cap. Flow
+$184M
Cap. Flow %
12.29%
Top 10 Hldgs %
43.16%
Holding
169
New
166
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$16.3M
3
ABBV icon
AbbVie
ABBV
+$15.6M
4
ZTS icon
Zoetis
ZTS
+$14.9M
5
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$12.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.18%
2 Healthcare 10.75%
3 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
26
Acadia Pharmaceuticals
ACAD
$4.74B
$14.6M 0.97%
+804,255
New +$11.1M
ZTS icon
27
Zoetis
ZTS
$30.4B
$14.2M 0.95%
+460,030
New +$14.9M
GILD icon
28
CALL
Gilead Sciences
GILD
$182B
$13.9M 0.92%
+2,706
New +$141K
REGN icon
29
PUT
Regeneron Pharmaceuticals
REGN
$81.7B
$12.8M 0.85%
+567
New +$132K
ELV icon
30
CALL
Elevance Health
ELV
$90.8B
$12.7M 0.85%
+1,551
New +$116K
ELV icon
31
PUT
Elevance Health
ELV
$90.8B
$12.7M 0.85%
+1,551
New +$116K
BHC icon
32
CALL
Bausch Health
BHC
$2.21B
$12.3M 0.82%
+1,425
New +$112K
ABBV icon
33
CALL
AbbVie
ABBV
$454B
$12.1M 0.81%
+2,926
New +$128K
ELN
34
CALL
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
$11.8M 0.79%
+8,329
New +$103K
TLT icon
35
iShares 20+ Year Treasury Bond ETF
TLT
$46.6B
$11.5M 0.77%
+104,050
New +$12.2M
EW icon
36
CALL
Edwards Lifesciences
EW
$49.3B
$11.4M 0.76%
+10,188
New +$121K
MYGN icon
37
CALL
Myriad Genetics
MYGN
$363M
$11.1M 0.74%
+4,126
New +$120K
ACOR
38
CALL
DELISTED
Acorda Therapeutics
ACOR
$10.7M 0.72%
+27
New +$111K
WCG
39
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
$10M 0.67%
+1,805
New +$101K
GILD icon
40
Gilead Sciences
GILD
$182B
$8.92M 0.6%
+174,108
New +$9.08M
SRPT icon
41
CALL
Sarepta Therapeutics
SRPT
$2.21B
$8.6M 0.57%
+2,259
New +$80.8K
CYBX
42
DELISTED
CYBERONICS INC
CYBX
$8.45M 0.56%
+162,625
New +$7.71M
ARNA
43
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.87M 0.52%
+1,021
New +$83.3K
LUMO
44
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$7.83M 0.52%
+441
New +$62.4K
BMY icon
45
CALL
Bristol-Myers Squibb
BMY
$131B
$7.58M 0.51%
+1,695
New +$73.6K
TEVA icon
46
PUT
Teva Pharmaceuticals
TEVA
$45.1B
$7.43M 0.5%
+1,895
New +$73.8K
ARNA
47
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.24M 0.48%
+940
New +$76.7K
AEGR
48
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$7.19M 0.48%
+1,135
New +$60.3K
ANTH
49
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$7.07M 0.47%
+238,423
New +$8.9M
KERX
50
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$6.88M 0.46%
+9,210
New +$72K
1
2
3 4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Sabby Management, which disclosed 169 positions worth $1.5B. Its ten largest holdings account for 43% of the portfolio.

Its largest position is Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, followed by Healthcare and Energy.

  • Sabby Management's largest Q2 2013 buy was Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.
  • Sabby Management's ten largest holdings make up 43% of its $1.5B portfolio in Q2 2013.
  • Sabby Management disclosed 169 positions in Q2 2013, its first 13F filing on record.

Based on Sabby Management's 13F filing for Q2 2013, filed 14 Aug 2013.